Indolent B-cell Non-Hodgkin Lymphoma (iNHL)
Oncology
Prevalence
30.0 / 100K
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target Indolent B-cell Non-Hodgkin Lymphoma (iNHL)?
There are 1 clinical trial targeting Indolent B-cell Non-Hodgkin Lymphoma (iNHL) tracked by BioSniper.
What is the prevalence of Indolent B-cell Non-Hodgkin Lymphoma (iNHL)?
The estimated prevalence of Indolent B-cell Non-Hodgkin Lymphoma (iNHL) is approximately 30.0 per 100,000 population.
Deep-dive into Indolent B-cell Non-Hodgkin Lymphoma (iNHL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis